Norepinephrine reuptake inhibitors and risk of antihypertensive treatment intensification and major adverse cardiovascular events in patients with stable hypertension and depression-Reference-Cited by-同舟云学术

Norepinephrine reuptake inhibitors and risk of antihypertensive treatment intensification and major adverse cardiovascular events in patients with stable hypertension and depression

Published:2022-05-09 Issue:6 Volume:42 Page:472-482
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Desai Raj¹^ORCID,Park Haesuk¹^ORCID,Brown Joshua D.¹,Mohandas Rajesh²,Smith Steven M.¹³⁴⁵^ORCID

Affiliation:

1. Department of Pharmaceutical Outcomes and Policy, College of Pharmacy University of Florida Gainesville Florida USA

2. Section of Nephrology, Department of Medicine Louisiana State University Health Sciences Center New Orleans Louisiana USA

3. Department of Pharmacotherapy and Translational Research, College of Pharmacy University of Florida Gainesville Florida USA

4. Division of Cardiovascular Medicine, Department of Medicine, College of Medicine University of Florida Gainesville Florida USA

5. Center for Integrative Cardiovascular and Metabolic Disease University of Florida Gainesville Florida USA

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/phar.2686

Reference27 articles.

1. Prevalence of Depression in Patients With Hypertension

2. Effects of Venlafaxine on Blood Pressure

3. Depression Is Associated With Decreased Blood Pressure, but Antidepressant Use Increases the Risk for Hypertension

4. The Effect of Antidepressant Therapy on Blood Pressure and Heart Rate Variability

5. Accelerated Hypertension after Venlafaxine Usage

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-induced cardiac toxicity and adverse drug reactions, a narrative review;Therapies;2023-10

2. Bibliometric analysis of global research trends in post-stroke depression: hotspots and frontiers;2023-01-05

3. SNRIs vs SSRIs: no increased risk of antihypertensive treatment intensification or MACE;Reactions Weekly;2022-05